P1152: RESULTS FROM A PHASE I PHARMACOKINETIC (PK) AND SAFETY STUDY OF TRPH-222, A NOVEL CD22-TARGETING ANTIBODY-DRUG CONJUGATE, IN PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (R/R NHL)
Main Authors: | F. J. Hernandez-Ilizaliturri, J. Kuruvilla, B. A. Christian, I. W. Flinn, S. E. Assouline, M. L. Ulrickson, D. J. Landsburg, M. Stuart, H. Lowman, N. Levin, D. Maetzel, N. N. Viller, A. MacLaren |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-06-01
|
Series: | HemaSphere |
Online Access: | http://journals.lww.com/10.1097/01.HS9.0000847476.69621.cd |
Similar Items
-
PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
by: Liu Rui, et al.
Published: (2023-08-01) -
685 A first-in-human Phase 1/2 clinical trial of SIRPαlow activated macrophages (SIRPant-M) for the treatment of R/R-NHL
by: Koby Kidder, et al.
Published: (2023-11-01) -
The Franks in the early Ideology of Frederick Barbarossa (1152-1158)
by: Vedran Sulovsky
Published: (2016-01-01) -
The career of Matilda of Boulogne as countess and queen in England, 1135-1152
by: Dark, P, et al.
Published: (2005) -
The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in C. elegans
by: Gregory M Davis, et al.
Published: (2018-12-01)